Abstract
Membrane transporters perform a central function in protecting the body from xenobiotics (either by preventing their absorption, limiting their distribution or promoting their elimination). Transporters can also take part in the traffic and compartmentalization of endogenous compounds. In some particular cases, they may favor drug absorption and/or distribution. Accordingly, they are of major importance from a pharmacological perspective. Transporter protein science is an emerging field, and their identification and characterization continue to evolve, with their medical and pharmaceutical impact being still far from being fully understood. In relation to drug kinetics, two gene families coding for polyspecific transporters are of particular importance: the ATP-binding cassette (ABC) transporters and the solute carrier (SLC) transporters. Both will be discussed in this last chapter of this volume.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Annaert P, Swift D, Lee JK et al (2007) Drug transport in the liver. In You G, Morris ME (eds). John Wiley & Sons, Inc., Hoboken
Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33:941–951
Borst P, Evers R, Kool M et al (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–1302
Carneiro A, Blakely R (2006) Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. J Biol Chem 281:24769–24780
Choi YH, Yu AM (2014) ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 20:793–807
Couyoupetrou M, Gantner ME, Di Ianni ME et al (2017) Computer-aided recognition of ABC transporters substrates and its application to the development of new drugs for refractory epilepsy. Mini Rev Med Chem 17:205–215
Daws L, Gould G (2011) Ontogeny and regulation of the serotonin transporter: Providing insights into human disorders. Pharmacol Ther 131:61–79
Di L, Keefer C, Scott DO et al (2012) Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. Eur J Med Chem 57:441–448
Eiden LE, Weihe E (2011) VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann N Y Acad Sci 1216:86–98
Erickson JD, Eiden LE (1993) Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J Neurochem 61:2314–2317
Fagiolino P (2017) Farmacocinética y biofarmacia. Parte I: principios fundamentales. UdelaR-FQ; FUNDAQUIM, Montevideo
Feldmann M, Koepp M (2016) ABC transporters and drug resistance in patients with epilepsy. Curr Pharm Des 22:5793–5807
Ferman C, Baladi M, McFadden L et al (2015) Regulation of the dopamine and vesicular monoamine transporters: Pharmacological targets and implications for disease. Pharmacol Rev 67:1005–1024
Ferreira RJ, Ferreira MJ, dos Santos DJ (2013) Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein. J Chem Inf Model 53:1747–1760
Forrest LR, Rudnick G (2009) The rocking bundle: A mechanism for ion-coupled solute flux by symmetrical transporters. Physiology (Bethesda) 24:377–386
Gether U, Andersen PH, Larsson OM et al (2006) Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol Sci 27:375–383
Hagenbuch B, Stieger B (2013) The SLCO (former SLC21) superfamily of transporters. Mol Asp Med 34:396–412
Homolya L, Váradi A, Sarkadi B (2003) Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors 17:103–114
Huwyler J, Wright MB, Gutmann H, Drewe J (2006) Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. Curr Drg Metab 7:119–126
Iannetti P, Spalice A, Parisi P (2005) Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 46:967–969
Katoh M, Nakajima M, Yamazaki H et al (2001) Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci 12:505–513
Kim RB (2002) Drugs as p-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 34:47–54
Koepsell H (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Asp Med 34:413–435
Kristensen A, Andersen J, Jørgensen T et al (2011) SLC6 neurotransmitter transporters: Structure, function, and regulation. Pharmacol Rev 63:585–640
Lawal HO, Krantz DE (2013) SLC18: vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Asp Med 34:360–372
Lhommé C, Joly F, Walker JL et al (2008) (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 26:2674–2682
Lohr K, Masoud S, Salahpor A et al (2017) Membrane transport as mediators of synaptic dopamine dynamic: implications for disease. Eur J Neurosci 11:3499–3511
Luna-Tortós C, Fedrowitz M, Löscher W (2008) Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmcology 55:1364–1375
Mao Q, Unadkat JD (2015) Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update. AAPS J 17:65–82
Matheny CJ, Ali RY, Yang X et al (2004) Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metab Dispos 32:1008–1014
Nanayakkara AK, Follit CA, Chen G, Williams NS, Vogel PD, Wise JG (2018) Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. Scientific Reports 8 (1)
Omiatek DM, Bressler AJ, Cans AS et al (2013) The real catecholamine content of secretory vesicles in the CNS revealed by electrochemical cytometry. Sci Rep 3:1447
Pereira CD, Martins F, Wiltfang J et al (2018) ABC transporters are key players in Alzheimer's disease. J Alzheimer Dis 61:463–485
Pérez-Tomás R (2006) Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13:1859–1876
Potschka H, Luna-Munguia H (2014) CNS transporters and drug delivery in epilepsy. Curr Pharm Des 20:1534–1542
Qian Y, Melikian HE, Rye DB et al (1995) Identification and characterization of antidepressant-sensitive serotonin transporter proteins using site-specific antibodies. J Neurosci 15:1261–1274
Rees DC, Johnson E, Lewinson O (2009) ABC transporters: The power to change. Nat Rev Mol Cell Biol 10:218–227
Reith ME, Blough BE, Hong WC et al (2015) Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend 147:1–19
Rudnick G, Steiner-Mordoch SS, Fishkes H et al (1990) Energetics of reserpine binding and occlusion by the chromaffin granule biogenic amine transporter. Biochemistry 29:603–608
Rudnick G (1998) Bioenergetics of neurotransmitter transport. J Bioenerg Biomembr 30:173–185
Russel FGM (2010) In: Pang KS, Rodrigues AD, Peter RM (eds) Transporters: importance in drug absorption, distribution, and removal. Springer, New York
Safa A (2004) Identification and characterization of the binding sites of P-Glycoprotein for multidrug resistance-related drugs and modulators. Curr Med Chem Anticancer Agents 4 (1):1–17
Salphaty L, Benet LZ (1998) Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol 55:387–395
Sarkadi B, Ozvegy-Laczka C, Német K et al (2004) BCG2 -- a transporter for all seasons. FEBS Lett 567:116–120
Sarkadi B, Homolya L, Szakács G et al (2006) Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86:1179–1236
Singh SK, Piscitelli CL, Yamashita A et al (2008) A competitive inhibitor traps LeuT in an open-to-out conformation. Science 322:1655–1661
Sitte H, Freissmuth M (2015) Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci 36:41–50
Spiller HA, Hays HL, Aleguas A Jr (2013) Overdose of drugs for attention-deficit hyperactivity disorder: Clinical presentation, mechanisms of toxicity, and management. CNS Drugs 27:531–543
Schlessinger A, Matsson P, Shima JE et al (2010) Comparison of human solute carriers. Protein Sci 19:412–428
Schlessinger A, Khuri N, Giacomini KM et al (2013) Molecular modeling and ligand docking for solute carrier (SLC) transporters. Curr Top Med Chem 13:843–856
Subramanian N, Schumann-Gillett A, Mark AE, O’Mara ML (2016) Understanding the accumulation of P-glycoprotein substrates within cells: The effect of cholesterol on membrane partitioning. Biochimica et Biophysica Acta (BBA) - Biomembranes 1858 (4):776–782
Sun YL, Patel A, Kumar P et al (2012) Role of ABC transporters in cancer chemotherapy. Chin J Cancer 31:51–57
Südhof TC (2004) The synaptic vesicle cycle. Annu Rev Neurosci 27:509–547
Sulzer D, Maidment NT, Rayport S (1993) Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 60:527–535
Sulzer D, Sonders MS, Poulsen NW et al (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406–433
Taft DR (2009) In: Hacker M, Bachmann K, Messer W (eds) Drug excretion. Academic Press, Burlington
Ter Beek J, Guskov A, Slotboom DJ (2014) Structural diversity of ABC transporters. J Gen Physiol 143:419–435
Tiwari AK, Sodani K, Dai CL et al (2011) Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 12:570–594
US Food and Drug Administration (2017a) In vitro metabolism and transporter-mediated drug-drug interaction studies. Guidance for industry
US Food and Drug Administration (2017b) Clinical drug interaction studies - Study design, data analysis, and clinical implications. Guidance for industry
Wacher VJ, Wu C-Y, Benet LZ, (1995) Overlap** substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Molecular Carcinogenesis 13 (3):129–134
Zhou SF (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310–322
Further Reading
Transporter science is an expanding field, and this chapter is only intended as an introduction to the topic. The reader may find deeper insight into some excellent volumes that specifically deal with the subject, such as the ones edited by You and Morris (Drug Transporters: Molecular Characterization and Role in Drug Disposition, Second Edition, Wiley, 2014); Pang, Rodrigues, and Peter (Enzyme- and Transporter-based Drug Drug Interactions. Progress and Future Challenges, Springer, 2010); or Ecker and Chiba (Transporters as Drug Carriers. Structure, Function, Substrates, Wiley-VCH, 2009)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Talevi, A., Bellera, C.L., Pesce, G. (2018). Drug Transporters. In: Talevi, A., Quiroga, P. (eds) ADME Processes in Pharmaceutical Sciences. Springer, Cham. https://doi.org/10.1007/978-3-319-99593-9_14
Download citation
DOI: https://doi.org/10.1007/978-3-319-99593-9_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99592-2
Online ISBN: 978-3-319-99593-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)